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Background: Tobramycin, used to treat respiratory exacerbations in cystic fibrosis (CF), is also a renal tubular toxin. Tubular dysfunction
leads to increased urinary levels of the proximal tubular lysosomal enzyme, N-acetyl-beta-d-glucosaminidase (NAG) and the proximal
tubular protein, retinol-binding protein (RBP). Hypermagnesuria and resulting hypomagnesaemia are indicative of more severe tubular
damage, occasionally seen following repeated courses of intravenous tobramycin. Using these biochemical markers we studied the effect of a
2-week course of this agent on tubular function.
Methods: Twenty-two children (11 boys) with CF were studied. Median age=10.9 years, range 3.1–16.4 years. All had a normal predicted
glomerular filtration rate (pGFR). They received tobramycin 3 mg/kg/dose tds. Urinary NAG, RBP, creatinine and plasma magnesium and
creatinine were assayed:
a) immediately before commencing tobramycin
b) immediately following the course
c) 4 weeks after the end of the course.Results: Mean log UrNAG and UrRBP rose significantly between time points a) and b) before falling to almost pre-treatment levels by time
c). Using two way ANOVA analysis the results for UrNAG and UrRBP were both highly statistically significant ( p <0.0001). Paired t-tests
on the logged values revealed highly significant differences between all time points for UrNAG and in the case of UrRBP for all other than a)
compared to c). In all patients plasma magnesium and pGFR remained within normal limits.
Conclusions: Intravenous tobramycin produces acute tubular injury, which showed evidence of almost complete recovery after 4 weeks. The
insult to the tubules was not sufficient to produce hypomagnesaemia in our study group. To assess cumulative tubular damage in more detail
it would be necessary to repeat this study after further courses of tobramycin. We recommend monitoring plasma magnesium during courses
of intravenous tobramycin.
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For many years respiratory exacerbations of CF in
childhood have been treated with inhaled or intravenous
aminoglycosides. Tobramycin is widely used and is admin-
istered twice daily if inhaled and between once and three
times a day if the intravenous route is used. It is typically
given intravenously during acute, severe pseudomonal4 (2005) 221 – 225ed by Elsevier B.V. All rights reserved.
Table 1
Geometric means, with 95% confidence intervals (CI), of urinary RBP and NAG recorded for all study patients at time points a) immediately before
commencing a course of intravenous tobramycin, b) immediately following the course and c) 4 weeks after the end of the course
Time UrRBP (Ag/mmol creatinine) UrNAG (IU/mmol creatinine)
Geometric mean Lower 95% CI Upper 95% CI Geometric mean Lower 95% CI Upper 95% CI
a) 44.0 30.7 62.9 0.244 0.195 0.306
b) 94.5 48.0 186.2 0.827 0.586 1.168
c) 44.1 32.2 60.4 0.345 0.270 0.441
S. Glass et al. / Journal of Cystic Fibrosis 4 (2005) 221–225222pulmonary infections. Although efficacious, tobramycin is a
well recognised nephrotoxin and while safe blood levels are
defined for single courses of tobramycin, repeated admin-
istrations are often required for children with CF. Concern
has been raised over the long term renal damage produced by
multiple exposures to intravenous tobramycin [1,2].
Tobramycin is primarily a proximal tubular cell toxin.
Mechanisms for its toxicity include binding to cell
membrane phospholipids, sequestration in proximal tubular
cell lysosomes and injury to mitochondrial respiration [3].
Most commonly tobramycin produces relatively minor
proximal tubular dysfunction leading to release from tubular
cells and therefore elevated urinary levels of N-acetyl-beta-
d-glucosaminidase (UrNAG), a primarily proximal tubular
lysosomal enzyme and retinol binding protein (UrRBP), a
proximal tubular protein [4]. Both UrNAG and UrRBP have
been widely used as markers of subtle renal tubular damage
[5,6]. After repeated intravenous courses more marked
tubular dysfunction leading to hypomagnesaemia [7],
aminoaciduria, glycosuria, etc. can be seen and rarely even
acute, non-oliguric, renal failure may ensue [8].
We studied the effects on renal tubular function of a
standard 14 day course of intravenous tobramycin using a
common UK dosage schedule. UrNAG and UrRBP were
used to detect minor changes in proximal tubular function.
Predicted glomerular filtration rate (pGFR) and plasma
magnesium were used to gauge more severe changes in
tubular performance. The effect of exposure to previous
courses of intravenous tobramycin was also reviewed.All patients: Geometric mean UrRBP .v. Time
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Fig. 1. All patients: Geometric mean UrRBP vs. Time.2. Materials and methods
Twenty-two children with CF were studied. All had been
diagnosed following a positive sweat test and mutation
analysis. Eleven were boys (mean age 9.7 years, range 3.1–
16.4 years).
Following an exacerbation of their respiratory symp-
toms with a presumed Pseudomonas aeruginosa infection,
they received intravenous tobramycin at a dose of 3 mg/
kg three times a day for 14 days. Trough tobramycin
concentration was measured after the third dose and if
within the therapeutic range (2 mg/l) was not repeated.
No patients had symptoms suggestive of a urinary tract
infection. All patients initially had a normal pGFR
determined by the Schwarz formula [9]. All patients
completed the course. None received concurrent inhaled
aminoglycosides. Three time points were chosen for
assessment:
a) immediately before starting tobramycin
b) immediately following the course of tobramycin
c) 4 weeks after the end of the course of tobramycin.
At each of the above points UrNAG, UrRBP, urinary
creatinine, plasma magnesium and plasma creatinine were
measured.
UrNAG activity was assayed using a kit method
(Boehringer Mannheim). Cresol–sulphonphthalein–gluso-
saminidine is used as substrate. Values are normalised forAll patients: Geometric mean UrNAG .v. Time
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Fig. 2. All patients: Geometric mean UrNAG vs. Time.
Table 2
Paired t-tests comparing log urinary RBP and NAG values at time points: a)
immediately before commencing a course of intravenous tobramycin, b)
immediately following the course and c) 4 weeks after the end of the course
Time point comparison log UrRBP log UrNAG
a) vs. b) p =0.0318 p <0.0001
a) vs. c) p =0.9524 (ns) p <0.0001
b) vs. c) p =0.0168 p <0.0001
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mmol creatinine [10].
UrRBP was measured by a commercial radioimmuno-
assay. The normal range, again normalised for urinary
creatinine, is less than 23.4 Ag/mmol creatinine [6].
The study was approved by the Local Research Ethics
Committee. Informed consent was obtained from patients
(where appropriate) and parents.3. Results
The results for both UrRBP and UrNAG were log
normally distributed. Their geometric means and 95%
confidence intervals at the three time points noted above
are as shown in Table 1.
These results are shown graphically for UrRBP and
UrNAG in Figs. 1 and 2, respectively. Using two way
ANOVA analysis the results for both UrRBP and UrNAG
were highly statistically significant with p<0.0001 in each
case. Paired t-tests on the logged values (Table 2) demon-
strated very significant statistical differences between all time
points for UrNAG. In the case of UrRBP only the comparison
between time points a) and c) failed to reach statistical
significance. All patients had a trough tobramycin concen-
tration of 2 mg/l or less and plasma magnesium and pGFR
remained within normal limits at each time point.
In order to assess whether there was any evidence of
early cumulative tubular damage related to prior exposure to
tobramycin, we stratified the study patients into 3 groupsTobramycin courses: Geometric m
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Fig. 3. Tobramycin courses: Geomdependent on the number of previous courses of intravenous
tobramycin received.
& 0–2 courses of intravenous tobramycin (9 children)
& 3–5 courses of intravenous tobramycin (8 children)
& 6 or more courses of intravenous tobramycin (5 children)
The results for UrRBP and UrNAG in these groups are
demonstrated in Figs. 3 and 4, respectively. However, there
were no statistically significant differences between the 3
groups, at any of the time periods, for either UrRBP or
UrNAG.
Pre-treatment levels of UrRBP, but not UrNAG, were
above the normal range in the 21 of 22 children with prior
exposure to intravenous tobramycin on at least 1 occasion
(Table 3).4. Discussion
Our data suggest that a single course of intravenous
tobramycin produces mild tubular dysfunction resulting in
abnormally high levels of UrRBP and UrNAG. This was
observed at the end of a 14 day regimen. However, 4 weeks
following tobramycin administration UrRBP values had
effectively returned to pre-treatment levels but for UrNAG
there remained a statistically significant difference between
this and pre-treatment levels. Therefore, in our study group
the tubular injury appeared to be completely reversible if
UrRBP is used as a marker of tubular damage but only
partially so if UrNAG is employed. Similar changes in
UrNAG during an intravenous tobramycin course have been
reported previously by Steinkamp et al. [11] although their
study documented a rapid and complete return to pre-
treatment levels in a smaller number of patients who also
received concurrent intravenous azlocillin. The changes in
UrRBP have not been published before.
Interestingly, pre-treatment levels of UrRBP, but not
UrNAG were above the normal range in all children whoean UrRBP .v. Time
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Fig. 4. Tobramycin courses: Geometric mean UrNAG vs. Time.
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provides some evidence that aminoglycosides may have
long term effects on renal tubular function and increases
concern as to the potential for cumulative damage from
repeated courses of aminoglycosides. These data would also
suggest that UrNAG levels fall to normal at some stage after
time point c).
Stratifying our data depending on prior intravenous
tobramycin exposure showed no statistically significant
difference between the groups although there are only a
small number of children in each category.
We were unable to demonstrate significant tubular
abnormalities. Plasma magnesium levels were normal in
all patients throughout the study period, as were pGFRs.Table 3
Pre-treatment levels of urinary RBP and NAG for all patients (21 of 22
children) who had received at least 1 previous course of intravenous
tobramycin
Previous
courses
UrRBP (Ag/mmol creatinine)
normal range<23.4
UrNAG (IU/mmol creatinine)
normal range<0.6
1–2 39.9 0.24
1–2 40.6 0.27
1–2 25.2 0.38
1–2 92.3 0.13
1–2 61.8 0.25
1–2 52.5 0.16
1–2 47.6 0.14
1–2 50.0 0.26
3–5 461.5 0.24
3–5 67.6 0.50
3–5 15.9 0.12
3–5 68.4 0.46
3–5 20.9 0.59
3–5 30.9 0.23
3–5 21.0 0.23
3–5 31.9 0.13
6 26.7 0.13
6 31.8 0.25
6 56.5 0.32
6 29.0 0.20
6 34.3 0.16
The number of prior courses for each patient is also recorded.Compared to many patients with CF, our group had received
relatively few courses of tobramycin. In children with
greater exposure to this agent there may be evidence of
cumulative renal tubulotoxicity. In order to study the
question of cumulative toxicity occurring with repeated
courses of tobramycin over many years either larger groups
of children who have received varying numbers of previous
courses or longitudinal studies would need to be performed.
Tobramycin is recognised to be less nephrotoxic than
gentamicin and a number of other aminoglycosides when
the concentration of these drugs within the kidney itself is
relatively low [3]. At relatively high renal concentrations in
animal models, tobramycin has the greater nephrotoxicity
[12]. However, in children with CF, tobramycin appears to
have the same effect on tubular function in the short term as
gentamicin. Godson et al. [13] demonstrated comparable
changes in UrNAG (and low molecular weight proteins)
following the intravenous administration of gentamicin to
children with CF.
There has been speculation as to whether aminoglyco-
sides administered via a nebuliser produces tubular adverse
effects. Steinkamp et al. reported that inhaled tobramycin
produced no alteration in UrNAG activity [11], but Ring et
al. demonstrated in those patients receiving gentamicin
inhalation a positive correlation between UrNAG and the
cumulative dose of nebulised gentamicin [14].
Since this study was completed Smyth et al. have
demonstrated that once daily tobramycin is equally effica-
cious to a three times daily regimen, with the potential for
reduced toxicity [15]. They assessed nephrotoxicity by
measuring changes in plasma creatinine and, in a sub-group,
UrNAG levels immediately before and after treatment. Our
study gives further evidence that a thrice daily regimen is
nephrotoxic, although ideally it should be repeated using a
once daily dosing schedule.
In view of the data published by Smyth et al. [15], a once
daily intravenous tobramycin regimen has now been
instituted in our unit. In addition a nebulised, preservative
free, formulation of tobramycin (TOBI\) has also been
introduced for long term use. It is usually given to patients
S. Glass et al. / Journal of Cystic Fibrosis 4 (2005) 221–225 225with more severe suppurative lung disease. Administration
of nebulised TOBI\ produces significant serum levels of
approximately 1 mg/l an hour after dosing [16]. The co-
administration of both intermittent intravenous and long
term nebulised aminoglycoside has the potential to cause
both acute toxicity and increase the risk of chronic renal
tubular damage. We have found that co-administration of
intravenous and nebulised therapy can result in the serum
tobramycin level increasing by 1 mg/l, potentially into the
toxic range [unpublished observations]. As such, it is now
our policy to discontinue nebulised TOBI\ during a course
of intravenous antibiotic therapy. Although TOBI\ is
intended for administration on an alternate monthly basis,
the potential for cumulative chronic renal tubular toxicity
with long term co-administration should also be considered.
In summary, the clinical implications of our data with
respect to long term renal function remain unclear, although
we would concur with Smyth et al. [15] that a once daily
regimen probably reduces nephrotoxicity. It is of concern
that many of our study patients have evidence of acute
tubular dysfunction especially as they are likely to receive
many further doses of tobramycin in the future. In view of
the as yet unknown tubular effects of cumulative exposure
we recommend monitoring plasma magnesium in all
patients with CF receiving intravenous tobramycin.Acknowledgements
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